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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Ultrasonography (US) cannot demonstrate all the etiologies of biliary
tract dilatation in patients with jaundice. Thus, we evaluated the etiologic yield of endosono-
graphy (EUS) for suspected obstructive jaundice when no definite pathology was found on US.
Additionally, we sought to identify the predictors of the most common etiologies.
Methods: We performed a retrospective review of 123 consecutive patients who had under-
gone EUS for suspected obstructive jaundice when no definite pathology was identified on US.
Results: Themost commondiagnoses included no pathological obstruction (nZ 43), pancreatobili-
ary malignancy (nZ 41), and choledocholithiasis (nZ 28). Pancreatobiliary malignancy was asso-
ciated with common bile duct (CBD) dilatation, and fever and elevated alanine aminotransferase
werepredictors of choledocholithiasis (p< 0.05). TheaccuracyofEUSwas 95.9% (118/123) forover-
all cause of suspected obstructive jaundice, 100% (40/40) for no pathological finding, 100% (23/23)
for ampullary cancer, 100% (13/13) for pancreatic cancer, 75% (3/4) for CBD cancer, and 92.9%
(26/28) for choledocholithiasis, respectively. Besides the two patients with focal chronic pancrea-
titis misdiagnosed as with pancreatic cancer, EUS missed the lesions in one CBD cancer patient and
two patients with choledocholithiasis. The overall accuracy of EUS in ascertaining pancreatobiliary
malignancy and choledocholithiasis was comparable (97.6%, 40/41 vs. 92.9%, 26/28; p > 0.05).
Conclusion: Marked CBD dilatation (12 mm) should remind us of the high risk of malignancy,
and the presence of CBD dilatation and fever is suggestive of choledocholithiasis. Negativehave no conflicts of interest relevant to this article.
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sonography for jaundice withou
ultrasound.
Findings
Age (y)
Sex (M/F)
Mean CBD diameter (mm)
Mean pancreatic duct
diameter (mm)
Body mass index (kg/m2)
Symptoms
Fever
Abdominal pain
Weight loss
Serum ALT > 40 IU/L
Elevated ALK-P (>338 U/L)
Serum amylase > 116 U/L
Elevated CA19-9 (>37 U/mL)
Elevated CEA (>5 ng/mL)
Diagnosis
No pathologic obstruction
Ampullary cancer
Pancreatic cancer
CBD cancer
Choledocholithiasis
Mirizzi’s syndrome
Gall bladder cancer
Chronic pancreatitis
Mucinous cystoadenocarcinoma
of the pancreas
Data are presented as % (n/N) unles
ALK-P Z alkaline phosphatase; AL
ferase; CA Z carbohydrate antigen;
CEA Z serum carcinoembryonic antEUS findings cannot assure any pathological obstruction in patients with clinically suspected
obstructive jaundice.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Clinical history, physical examination, and laboratory tests
may identify up to 90% of patients with possible obstructive
jaundice, but no pathological obstruction of the biliary
tract sometimes can be encountered in patients with sus-
pected obstructive jaundice.1 Pancreatobiliary malignancy
and choledocholithiasis are the most common causes of
obstructive jaundice, and imaging modalities are required
for demonstrating the level and the etiology of biliary tract
obstruction to aid further management.
Ultrasonography (US) is a noninvasive, inexpensive, and
easily accessible diagnostic tool, and it is crucial for the
identification and evaluation of the cause of suspected
obstructive jaundice. Nonetheless, it is hard to visualize
both the distal part of the common bile duct (CBD) and the
papillary area clearly with US because bowel gas and
abdominal fat often interfere with the transmission of thetients undergoing endo-
t definite pathology on
Mean  SD or proportion
61.3  14.4 (n Z 123)
88/35 (n Z 123)
11.9  4.8 (n Z 123)
2.6  1.6 (n Z 123)
22.3  3.5 (n Z 88)
16.9 (21/123)
69.4 (86/123)
15.3 (19/123)
76.3 (90/118)
67.0 (61/91)
34.4 (22/64)
75.0 (54/72)
20.6 (14/68)
32.5 (40/123)
18.6 (23/123)
10.6 (13/123)
3.3 (4/123)
22.8 (28/123)
0.8 (1/123)
0.8 (1/123)
9.8 (12/123)
0.8 (1/123)
s otherwise indicated.
T Z alanine aminotrans-
CBD Z common bile duct;
igen.ultrasound beam. It is reported by some authors that the
accuracy of US in demonstrating the level and the etiology
of biliary tract obstruction is 27e60% and 23e38%,
respectively.2,3
Endoscopic retrograde cholangiopancreatography
(ERCP) is best reserved as a therapeutic tool for the risks of
pancreatitis, cholangitis, hemorrhage, perforation, and
fatality. Computed tomography (CT) can be used to eval-
uate the extrahepatic biliary tree and has the advantages
of noninvasiveness, operator independence, and high
technical achievement rate. Nonetheless, CT carries the
risks of radiation exposure and the use of contrast agents
can lead to kidney injury or allergic reaction. Magnetic
resonance imaging (MRI) is useful for assessing the extra-
hepatic biliary tree, but its accuracy decreases in the case
of scanty fat planes or little fluid contained in the CBD. In
addition, MRI cannot be applied to patients with claustro-
phobia or implanted electronic devices.
Similar to ERCP, endosonography (EUS) provides a direct
endoscopic view of the periampullary area. With additional
high-frequency ultrasound, EUS provides an excellent
sonographic evaluation of the extrahepatic biliary tree,
pancreas, and the duodenal wall. However, the disadvan-
tages of EUS include its operator dependence, equipment
inaccessibility, and patient discomfort during endoscopic
study.
The best diagnostic studies for suspected obstructive
jaundice of unknown cause remain uncertain.4 We under-
took this study to evaluate the etiologic yield of EUS for
suspected obstructive jaundice with no definite pathology
identified during US. We also determined the predictors of
the most common etiologies of obstructive jaundice,
including pancreatobiliary malignancy and
choledocholithiasis.Materials and methods
Patients
Patients who met the following criteria were included in
the study: (1) serum total bilirubin >1.2 mg/dL; (2)
abdominal US showing the diameter of the CBD >7 mm; (3)
the etiology of potential obstruction in the biliary tract was
not obvious on abdominal US; and (4) had been referred for
EUS. The definition of suspected obstructive jaundice
included the first three criteria. Patients with a history of
choledocholithiasis prior to undergoing abdominal US were
excluded.
From March 1998 to March 2010, we retrospectively
enrolled 123 patients who underwent EUS for suspected
obstructive jaundice and for whom a definite pathology was
not found during the initial US (Table 1). Among the 123
patients, 66 underwent CT and 45 underwent MRI (Fig. 1).
EUS, MRI, CT, and ERCP were performed within 48 hours of
finding no visible pathology on US. It was unusual for
Figure 1 Flowchart of patients undergoing imaging for the diagnosis of suspected obstructive jaundice, but without definite
pathology on ultrasound.
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Table 2 Accuracy of computed tomography (CT), mag-
netic resonance imaging (MRI), and endosonography (EUS) in
the evaluation of suspected obstructive jaundice without
definite pathology on ultrasound.
Diagnosis CT MRI EUS
No pathologic
obstruction
89.5
(17/19)
93.3
(14/15)
100 (40/40)
Ampullary cancer 18.8
(3/16)
33.3
(3/9)
100 (23/23)
Pancreatic cancer 40
(4/10)
50
(1/2)
100 (13/13)
Common bile duct
cancer
0
(0/1)
0
(0/3)
75 (3/4)
Choledocholithiasis 38.5
(5/13)
70
(7/10)
92.9 (26/28)
Mirizzi’s syndrome 100
(1/1)
100 (1/1)
Gall bladder cancer 100
(1/1)
100 (1/1)
Chronic pancreatitis 40
(2/5)
60
(3/5)
83.3 (10/12)
Mucinous
cystoadenocarcinoma
of the pancreatic
head
100
(1/1)
100 (1/1)
Overall 50
(33/66)
64.4
(29/45)
95.9 (118/123)
Data are presented as % (n/N) unless otherwise indicated.
Endosonography for suspected obstructive jaundice 823patients to undergo both CT and MRI in the same period due
to government insurance regulations. Nonetheless, for
suspected obstructive jaundice, it was the clinician’s de-
cision whether or not to perform CT or MRI.
The mean patient age was 61.3  14.4 years (male/fe-
male: 88/35). Abdominal pain (69.4%, 86/123), followed by
fever (16.9%, 21/123), were the most common symptoms.
The final diagnosis was determined by ERCP, pathological
specimens from biopsy or surgery, or clinical follow-up of
more than 6 months. The most common diagnoses included
no pathological obstruction (n Z 43), pancreatobiliary
malignancy (nZ 41), and choledocholithiasis (nZ 28). The
definition of body weight loss was unintentional weight loss
of 5% in 6 months. Elevated alanine aminotransferase
(ALT) was defined as serum ALT >40 IU/L, elevated serum
alkaline phosphatase (ALK-P) was >338 U/L, elevated
serum carbohydrate antigen 19-9 (CA19-9) was >37 U/mL,
and elevated serum carcinoembryonic antigen (CEA) was
>5 ng/mL. This study was approved by the local institu-
tional review board (Show Chwan Memorial Hospital, SCMH
IRB No: 991204).
EUS
EUS was performed with the Olympus oblique-viewing GF-
UM 20 echoendoscope (Olympus Co., Tokyo, Japan). The
echoendoscope was equipped with a radial scan transducer
and with dual frequencies of 7.5 MHz and 12 MHz. The
method of combining a water-filled balloon at theechoendoscope tip and distilled water infusion into the
lumen of the gastrointestinal tract was used for endo-
sonographic visualization. The major duodenal papilla,
pancreas, visceral vessels, gallbladder, and the extrahe-
patic biliary tract were visualized by gradually withdrawing
the echoendoscope from the second portion of the duo-
denum into the stomach. All endosonographic images were
recorded on videotape for documentation and review.
CT
The patients ingested a water-soluble contrast agent 60
minutes prior to conventional CT (Hi-Speed scanner, GE
Medical Systems, Milwaukee, WI, USA), and 150 mL of
Omnipaque 240 (Iohexol; Nycomed Imaging, Oslo, Norway)
was intravenously administered at a rate of 2 mL/second
immediately prior to scanning. The CT was performed using
a dual-slice technique with a slice thickness of 5 mm
covering 20 cm, 120 kVp at 220e240 mA, scan time of 30
seconds, pitch of 1, and 4-mm incremental axial
reconstruction.
MRI
The T2-weighted, respiratory-triggered fast spin-echo MRI
and T1-weighted breath-hold multislice spoiled gradient-
echo MRI of the liver and pancreas were done using a
conventional 1.5-T MRI scanner (Sigma Excite; GE medical
Systems, Milwaukee, WI, USA). The patients received a
bolus of 0.1 mmol/kg gadopentetate dimeglumine (Mag-
nevist; Schering, Berlin, Germany) followed by automated
injection of 30 mL of saline flush at 2 mL/second (Mal-
linckrodt, Optistar LE, OH, Cincinnati, USA) during the
multislice spoiled gradient-echo sequence. Magnetic reso-
nance cholangiopancreatography was performed with a
breath-hold single-shot fast spin-echo sequence. Sequen-
tial, single-slice imaging of eight sections was acquired with
a 40-mm section thickness, no intersection gap, an effec-
tive echo time of 950 ms, 0.5 signal acquisition, 28-cm field
of view with a 75% rectangular field of view, 320  224
matrix, and 31.5 kHz bandwidth. The thick slices were ac-
quired in the coronal and 10 coronal oblique planes with a
2-second acquisition time for each slice.
Statistical analysis
SPSS (SPSS Inc., Chicago, IL, USA) was used for the statis-
tical analyses. The categorical variables are summarized by
numbers of cases and percentages; continuous variables are
described by means  standard deviations. Student t test,
Chi-square analysis with Fisher exact test, analysis of
variance, and logistic regression analysis were performed as
appropriate. A p value <0.05 was considered statistically
significant.
Results
Table 2 shows the accuracy of CT, MRI, and EUS in the
evaluation of suspected obstructive jaundice without defi-
nite pathology on US. The accuracy of EUS was 95.9% (118/
Figure 2 Endosonogram obtained from a patient with chol-
edocholithiasis shows a stone with an acoustic shadow (arrow)
in the common bile duct.
Table 3 Results of the 20 patients with inaccurate diag-
nosis by either magnetic resonance imaging (MRI) or echo-
sonography (EUS).
MRI diagnosis EUS diagnosis Final diagnosis (n)
Choledocholithiasis Chronic
pancreatitis
Chronic
pancreatitis (1)
Choledocholithiasis CBD cancer CBD cancer (1)
Choledocholithiasis Ampullary cancer Ampullary cancer
(1)
No pathology CBD cancer CBD cancer (1)
No pathology Ampullary cancer Ampullary cancer
4(5)
No pathology Choledocholithiasis Choledocholithiasis
(3)
Chronic
pancreatitis
Pancreatic cancer Pancreatic cancer
(1)
Pancreatic cancer Chronic
pancreatitis
Chronic
pancreatitis (1)
Pancreatic cancer No pathology No pathology (1)
Choledocholithiasis No pathology Choledocholithiasis
(1)
No pathology Choledocholithiasis CBD cancer (1)
Pancreatic cancer Chronic
pancreatitis (2)
No pathology Choledocholithiasis
(1)
CBD Z common bile duct.
824 C.-H. Chen et al.123) for overall cause of suspected obstructive jaundice,
100% (40/40) for no pathological finding, 100% (23/23) for
ampullary cancer, 100% (13/13) for pancreatic cancer, 75%
(3/4) for CBD cancer, and 92.9% (26/28) for chol-
edocholithiasis, respectively. The accuracy of CT was 50%
(33/66) for overall cause of suspected obstructive jaundice,
89.5% (17/19) for no pathological finding, 18.8% (3/16) for
ampullary cancer, 40% (4/10) for pancreatic cancer, 0% (0/
1) for CBD cancer, and 38.5% (5/13) for choledocholithiasis,
respectively. The accuracy of MRI was 64.4% (29/45) for
overall cause of suspected obstructive jaundice, 93.3% (14/
15) for no pathological finding, 33.3% (3/9) for ampullary
cancer, 50% (1/2) for pancreatic cancer, 0% (0/3) for CBD
cancer, and 70% (7/10) for choledocholithiasis,
respectively.
The overall accuracy of EUS for detecting pan-
creatobiliary malignancy and choledocholithiasis was com-
parable (97.6%, 40/41 vs. 92.9%, 26/28; p > 0.05). EUS had
97.5% (39/40) sensitivity, 97.6% (81/83) specificity, 95.1%
(39/41) positive predictive value, and 98.8% (81/82) nega-
tive predictive value for diagnosing periampullary carci-
noma; EUS had 92.9% (26/28) sensitivity, 97.9% (93/95)
specificity, 92.9% (26/28) positive predictive value, and
97.9% (93/95) negative predictive value for diagnosing
choledocholithiasis (Fig. 2). The accuracy of EUS was not
related to the presence of choledocholithiasis (90%, 27/30
vs. 96.8%, 90/93, p Z 0.16), pancreatobiliary malignancy
(95.1%, 39/41 vs. 95.1%, 78/82, pZ 0.99), main pancreatic
duct diameter >2 mm (96.8%, 30/31 vs. 94.6%, 87/92,
pZ 0.99), CBD diameter 12 mm (93%, 52/57 vs. 97%, 64/
66, p Z 0.41), elevated serum carcinoembryonic antigen
(92.9%, 13/14 vs. 92.6%, 50/54, pZ 0.99), elevated CA19-9
(94.4%, 51/54 vs. 100%, 18/18, p Z 0.57), elevated ALK-P
(95.1%, 58/61 vs. 96.7%, 29/30, p Z 0.99), serum
ALT > 40 IU/L (94.4%, 85/90 vs. 96.4%, 27/28, p Z 0.99),
and body mass index (<18.5 kg/m2: 87.5%, 7/8 vs.
18.5 kg/m2 and <24 kg/m2: 94%, 47/50 vs. 25 kg/m2:
100%, 28/28, p Z 0.26).
Table 3 shows the results of the 20 patients with inac-
curate diagnoses by either MRI or EUS. In addition to thetwo patients with focal chronic pancreatitis misdiagnosed
with chronic pancreatitis by EUS without fine-needle aspi-
ration biopsy, EUS missed the diagnosis of one patient with
CBD cancer and two patients with choledocholithiasis. The
T1N0 CBD cancer was misdiagnosed on EUS as cholangitis
with sludge stones; nevertheless, the misdiagnosis of two
patients with choledocholithiasis made by EUS was cor-
rected by MRI in one patient.
The 16 patients misdiagnosed by MRI included one case
of no pathological finding, two cases of chronic pancrea-
titis, three cases of CBD cancer, six cases of ampullary
cancer, one case of pancreatic cancer, and three cases of
choledocholithiasis. Notably, EUS could have corrected all
of the misdiagnoses except for one case of CBD cancer. We
noted that ampullary cancer was relatively hard for MRI to
detect because it missed six cases of ampullary cancer
(66.7%, 6/9) in our study.
Table 4 shows the results of univariate and binary lo-
gistic regression analyses of factors associated with malig-
nancy. Abdominal pain, unintentional loss of 5% body
weight in 6 months, elevated CA19-9, elevated ALK-P, and
CBD dilatation were all associated with malignancy. Fever
and elevated ALT were associated with choledocholithiasis.
Binary logistic regression analysis indicated that CBD dila-
tation was the only positive predictor of malignancy
whereas fever and elevated ALT were the positive pre-
dictors of choledocholithiasis (p < 0.05).
The receiver operating characteristic (ROC) curve was
plotted to determine the optimal cut-off level of CBD
diameter for predicting malignant obstruction (Fig. 3). A
Table 4 Univariate and binary logistic regression analyses of factors associated with malignancy and choledocholithiasis.
Univariate analysis of factors associated with malignancy and choledocholithiasis*
Variables Malignancy p Choledocholithiasis p
Yes No Yes No
Male/female 28/13 60/22 >0.05 19/11 69/24 >0.05
Age 65 y 25/63 (39.7) 16/60 (26.7) >0.05 17/63 (27.0) 13/60 (21.7) >0.05
Fever 5/21 (23.8) 36/102 (35.3) >0.05 10/21 (47.6) 20/102 (19.6) <0.05
Abdominal pain 21/86 (24.4) 20/37 (54.1) <0.005 24/86 (27.9) 6/37 (16.2) >0.05
Weight loss 11/19 (57.9) 30/104 (28.8) <0.05 2/19 (10.5) 28/104 (26.9) >0.05
Elevated CEA 5/14 (35.7) 20/54 (37.0) >0.05 2/14 (14.3) 14/54 (25.9) >0.05
Elevated CA19-9 23/54 (42.6) 3/18 (16.7) <0.05 11/54 (20.4) 4/18 (22.2) >0.05
Elevated ALK-P 30/61 (49.2) 6/30 (20.0) <0.05 15/61 (24.6) 5/30 (16.7) >0.05
Elevated amylase 6/22 (27.3) 16/42 (38.1) >0.05 7/22 (31.8) 10/42 (23.8) >0.05
Elevated ALT 34/90 (37.8) 7/28 (25.0) >0.05 25/90 (27.8) 3/28 (10.7) <0.05
Main pancreatic
duct >2 mm
12/31 (38.7) 29/92 (31.5) >0.05 7/31 (22.6) 23/92 (25.0) >0.05
CBDa 3/19/19 23/40/19 0.001 2/17/11 24/42/27 >0.05
Binary logistic regression analysis of factors associated with malignancy and choledocholithiasis
Variables Malignancy Choledocholithiasis
OR 95% CI Variables OR 95% CI
Abdominal pain 0.3 0.06e1.27 Fever 4.6 1.62e13.20
Weight loss 3.5 0.19e66.12 Elevated ALT 3.9 1.01e14.92
Elevated CA19-9 2.9 0.57e14.55
Elevated ALK-P 4.5 0.48e42.31
CBD group 2.7 1.07e7.06
Data are presented as n/N (%) unless otherwise indicated.
ALK-PZ alkaline phosphatase; ALTZ alanine aminotransferase; CAZ carbohydrate antigen; CBDZ common bile duct; CEAZ serum
carcinoembryonic antigen.
a CBD group: <8 mm, 8 mm and <12 mm, and 12 mm.
* The covariates are shown in the table (with p < 0.05 in univariate analysis).
Endosonography for suspected obstructive jaundice 825CBD diameter of 11.5 mm (arrow) resulted in 65.9% sensi-
tivity and 63.4% specificity for the presence of malignant
obstruction. A CBD diameter of 12.3 mm (hollow arrow)
resulted in 46.3% sensitivity and 76.8% specificity for the
presence of malignant obstruction. The AUC was 0.702 and
CBD  12 mm could achieve specificity of about 75.0% for
predicting malignant obstruction.
Additionally, the ROC curve was plotted to determine
the cut-off level of ALT for predicting choledocholithiasis
(Fig. 4). An ALT level of 40 IU/L (arrow) resulted in 89.3%
sensitivity and 27.8% specificity for the presence of chol-
edocholithiasis. An ALT level of 80 IU/L (hollow arrow)
resulted in 60.7% sensitivity and 45.6% specificity for the
presence of choledocholithiasis. The AUC (0.608) was low
and elevated ALT could not achieve a high specificity for
predicting the presence of choledocholithiasis in our study.Discussion
Jaundice raises concerns about the possibility of biliary
tract obstruction, but biliary tract obstruction does not
necessarily mean CBD dilatation. Although ascertaining
the presence of obstructive jaundice is essential to ensure
the appropriate management, the best method for
determining the etiology of suspected obstructivejaundice without definite pathology shown on US remains
uncertain. US remains a convenient screening modality for
the presence of obstructive jaundice in daily practice, but
the whole extrahepatic biliary tract is visible on US in only
60% of patients, in 80% by conventional CT, and in 98% by
EUS.5 Our results consistently showed that conventional CT
was poor for assessing the etiology of CBD dilatation;
multi-slice CT was not utilized in our study. EUS and MRI
are regarded as low-risk diagnostic modalities with
excellent performance for the diagnosis of pan-
creatobiliary diseases, but it remains debatable whether
EUS or MRI is the optimal diagnostic modality for the
etiologic diagnosis of suspected obstructive jaundice
without pathology on US.6
We identified malignancies in 33.3% (41/123) of our pa-
tients, which should remind us that the possibility of ma-
lignancy is far from negligible in patients with suspected
obstructive jaundice, even when no definite pathology is
demonstrated on US. It takes 2e3 days for the extrahepatic
ducts and 1 week for the intrahepatic ducts to dilate after
the onset of obstruction.7,8 The clinical diagnosis of
obstructive jaundice is challenging, and one cannot rely
solely on the CBD diameter; nonetheless, the present re-
sults are consistent with the literature, which suggests that
the degree of CBD dilatation deserves more attention
concerning the possibility of malignant obstruction.6
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Figure 3 Receiver operating characteristic (ROC) curve
plotted to determine the cut-off level of common bile duct
(CBD) diameter for predicting malignant obstruction. A CBD
diameter of 11.5 mm (arrow) resulted in 65.9% sensitivity and
63.4% specificity for detecting malignant obstruction. A CBD
diameter of 12.3 mm (hollow arrow) resulted in 46.3% sensi-
tivity and 76.8% specificity for detecting malignant obstruc-
tion. The area under the curve was 0.702.
826 C.-H. Chen et al.Although Karvonen et al9 supposed that the degree of
CBD dilatation does not aid in the differential diagnosis
between choledocholithiasis and malignant obstruction,
their data still showed that the diameter of CBD was
significantly greater in malignant obstruction and the
diagnostic efficiency of CBD diameter was significant when
compared with the random values in the ROC analysis. The
AUC (Fig. 3) for CBD was moderate (0.702) for the predic-
tion of malignant obstruction. However, it is essential to
note that the absence of a dilated CBD (12 mm) did not
necessarily mean a lack of pancreatobiliary malignancy due
to the low sensitivity (<50%) for a dilated CBD to predict
the presence of the pancreatobiliary malignancy. We
recommend that marked CBD dilatation (12 mm) should
remind us of the high risk of malignancy and the need to
apply EUS first or even after a negative MRI study in patients
with suspected obstructive jaundice because the accuracy
of EUS is high (97.6%, 40/41); it can complementarily catch
a missed MRI diagnosis of pancreatobiliary malignancy.
Our results were consistent with the literature in
showing that elevated ALT was more likely to be seen in
obstructive stone disease, rather than in malignant biliary
stricture.10 However, we did not recommend solely relying
on elevated ALT to predict the presence of chol-
edocholithiasis because the AUC (Fig. 4) was low (0.608) in
our study. Consistent with the literature, the sensitivity andspecificity of elevated ALT in predicting the presence of
choledocholithiasis cannot go parallel even if it is statisti-
cally significant in our study.10e12 By contrast, fever is
generally agreed to be both a valuable sign and strong
predictor of choledocholithiasis.13,14
Because of its small size, the small amount of fluid
contained in the tapering biliary tree and gas interference
from the bowels, the ampulla of Vater is regarded as a blind
spot for MRI, and an unexplained dilated CBD on MRI
certainly cannot exclude the presence of ampullary tu-
mors.15 CT also tends to miss ampullary tumors in the
presence of the small tumor size and loss of the fat plane in
cancer patients.16,17 With an endoscopic view of the
ampulla and the long ultrasonographic view of the extra-
hepatic duct from the liver hilum proximal to the ampulla
of Vater distally, our results consistently support that EUS
has emerged as the first choice for visualizing the peri-
ampullary area.
EUS is sensitive for the detection of pancreatic cancer
<3 cm in size; such small tumors are easily missed on US
and yet they are responsive to surgery.18,19 Conventional
CT, as utilized in our study, has poor tumor-to-pancreas fat
plane contrast during the arterial phase of enhancement to
demonstrate pancreatic tumors.20 MRI has inherently high
soft tissue contrast and resolution to detect subtle
pancreatic lesions. Nonetheless, in our study, the number
of recruited pancreatic cancer patients who underwent MRI
was small. The sensitivity of US, CT, and MRI for the
detection of distal CBD carcinoma is poor because chol-
angiocarcinoma may only cause bile duct stricture or biliary
wall thickening with poor contrast enhancement.21 Chol-
angiocarcinoma may present as a papillary or hypoechoic
mass on EUS, but it becomes hard for EUS to detect when
the CBD wall is only subtly changed. Because pancreatic
cancer tends to be too advanced to be missed on US and
cholangiocarcinoma is epidemiologically rare, the compar-
ison between EUS and MRI in the diagnosis of pancreatic
cancer and cholangiocarcinoma did not significantly differ
in our study.
Our results are consistent with the literature showing
that EUS is superior to or comparable to MRI for diagnosing
choledocholithiasis.6 Stone size is not always a discrimi-
nating factor for MRI and EUS in the demonstration of
choledocholithiasis, and the detection rate is comparable
in both modalities.6 However, stones impacted in the
ampulla or biliary sludge composed of 1e2-mm particles
can be missed on MRI. Although magnetic resonance chol-
angiopancreatography with native axial acquisition is
excellent to depict small stones, MRI cannot depict biliary
sludge presenting as only a fluid-fluid level of different
signal intensity. In our study, three patients with chol-
edocholithiasis missed on MRI were complementarily
detected on EUS. EUS and MRI have emerged as the main
diagnostic modalities for patients at intermediate risk of
choledocholithiasis, and ERCP has evolved into a thera-
peutic procedure for patients at high risk of
choledocholithiasis.22
There are some limitations in our study. First, this is a
retrospective study. Nevertheless, this study is represen-
tative of real clinical situations for suspected obstructive
jaundice without definite pathology on US. Second, the
accuracy of CT 50% (33/66) and MRI 64.4% (29/45) could be
Figure 4 Receiver operating characteristic (ROC) curve
plotted to determine the cut-off level of alanine aminotrans-
ferase (ALT) for predicting choledocholithiasis. An ALT level of
40 IU/L (arrow) resulted in 89.3% sensitivity and 27.8% speci-
ficity for detecting choledocholithiasis. An ALT level of 80 IU/L
(hollow arrow) resulted in 60.7% sensitivity and 45.6% speci-
ficity for detecting choledocholithiasis. The area under the
curve was 0.608.
Endosonography for suspected obstructive jaundice 827underestimated because not all patients referred for CT or
MRI to study the etiology of suspected obstructive jaundice
without definite pathology on US were enrolled in this
study. Our inherent limitation of this retrospective study
was that we only recruited patients referred for EUS and
some patients would not undergo EUS until no definite
diagnosis could be made by CT or MRI. Conventional
enhanced CT, rather than multi-slice CT, with a slice
thickness of 5 mm also could have contributed to the lower
accuracy of CT for the etiologic yield. In addition, the lower
accuracy of MRI in our study might also be attributed to the
greater proportion (26.7%, 12/45) of patients with ampul-
lary cancer or CBD cancer referred for MRI. Third, the case
numbers of pancreatic cancer and cholangiocarcinoma
were small in this study. Most pancreatic cancers are
detected by US in symptomatic patients, and the occur-
rence of cholangiocarcinoma is epidemiologically rare.
However, the advantage of EUS in demonstrating pan-
creatobiliary malignancy, particularly ampullary cancer,
still can be clarified in this study. Previous reports of the
accuracy of EUS for demonstrating choledocholithiasis
mainly focused on biliary dilatation or acute pancreatitis
whereas our study of EUS mainly focused on suspected
obstructive jaundice, yet our results consistently showed
that EUS was accurate in detecting choledocholithiasis.15
Fourth, the case numbers of CT and MRI were also rela-
tively small in our study. However, it was not our aim to
compare the accuracy among the three diagnostic modal-
ities of CT, MRI, and EUS. It was unusual for the patients to
undergo both CT and MRI in the same period considering
government regulations on insurance coverage.We concluded that marked CBD dilatation (12 mm)
should raise concern about malignancy and the presence of
fever should raise concern for choledocholithiasis. EUS is an
accurate sonographic modality for the etiologic diagnosis of
clinically suspected obstructive jaundice with no definite
pathology on US, but negative EUS findings cannot assure
the lack of biliary obstruction.References
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